L. Degenhardt, H. A. Whiteford, and A. J. Ferrari, Global burden of disease attributable to illicit drug use and dependence: findings from the global burden of disease study, Lancet, vol.382, pp.1564-1574, 2010.

H. Jalal, J. M. Buchanich, and M. S. Roberts, Changing dynamics of the drug overdose epidemic in the United States from 1979 through, Science, vol.361, issue.6408, p.1184, 2016.

H. Hedegaard, L. Chen, and M. Warner, Drug-poisoning deaths involving heroin: united States, NCHS Data Brief, vol.190, pp.1-8, 2000.

L. H. Chen, H. Hedegaard, and M. Warner, Drug-poisoning deaths involving opioid analgesics: United States, NCHS Data Brief, issue.166, pp.1-8, 1999.

L. Scholl, P. Seth, and M. Kariisa, Drug and opioid-involved overdose deaths -United States, MMWR Morb Mortal Wkly Rep, vol.67, pp.1419-1427, 2018.

N. D. Volkow, E. B. Jones, and E. B. Einstein, Prevention and treatment of opioid misuse and addiction: a review, JAMA Psychiatry, vol.76, pp.208-216, 2019.

T. Kovitwanichkanont and C. A. Day, Prescription opioid misuse and public health approach in Australia, Subst Use Misuse, vol.53, pp.200-205, 2018.

A. N. Nafziger and R. L. Barkin, Opioid Therapy in Acute and Chronic Pain, J Clin Pharmacol, vol.58, issue.9, pp.1111-1122, 2018.

M. S. Toce, P. R. Chai, and M. M. Burns, Pharmacologic treatment of opioid use disorder: a review of pharmacotherapy, adjuncts, and toxicity, J Med Toxicol, vol.14, pp.306-322, 2018.

L. Tanum, K. K. Solli, and Z. E. Latif, Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial, JAMA Psychiatry, vol.74, issue.12, pp.1197-1205, 2017.

J. D. Lee, E. V. Nunes, and P. Novo, Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial, Lancet, vol.391, pp.309-318, 2018.

M. C. Blanco-gandía, R. , and M. , Pharmacological treatments for opiate and alcohol addiction: A historical perspective of the last 50 years, Eur J Pharmacol, vol.836, pp.89-101, 2018.

H. D. Kleber, Methadone maintenance 4 decades later: thousands of lives saved but still controversial, JAMA, vol.300, pp.2303-2305, 2008.

V. P. Dole and M. Nyswander, A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride, JAMA, vol.193, pp.646-650, 1965.

E. Fournier, A. Gorceix, and P. Bourdon,

, Ann Med Internet (Paris), vol.125, pp.447-452, 1974.

P. Deniker, H. Lôo, and E. Zarifian,

, Ann Med Internet (Paris), vol.125, pp.459-462, 1974.

, Alderks CE Trends in the use of methadone, buprenorphine, and extended-release naltrexone at substance abuse treatment Facilities: 2003-2015 (update). The CBHSQ Report

, Substance Abuse and Mental Health Services Administration (US), 2013.

Y. Hser, E. Evans, and D. Huang, Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial: outcomes of buprenorphine versus methadone, Addiction, vol.111, pp.695-705, 2016.

S. Nielsen, B. Larance, and N. Lintzeris, Opioid agonist treatment for patients with dependence on prescription opioids, JAMA, vol.317, pp.967-968, 2017.

E. C. Strain, M. L. Stitzer, and I. A. Liebson, Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index, J Clin Psychopharmacol, vol.16, pp.58-67, 1996.

M. Dematteis, M. Auriacombe, D. 'agnone, and O. , Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus, Expert Opin Pharmacother, vol.18, pp.1987-1999, 2017.

?. First, European expert-based guidance for using OMTs

L. Sordo, G. Barrio, and M. J. Bravo, Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies, BMJ, vol.357, p.1550, 2017.

S. M. Giacomuzzi, Y. Riemer, and M. Ertl, Buprenorphine versus methadone maintenance treatment in an ambulant setting: a health-related quality of life assessment, Addiction, vol.98, pp.693-702, 2003.

A. M. Ponizovsky and A. Grinshpoon, Quality of life among heroin users on buprenorphine versus methadone maintenance, Am J Drug Alcohol Abuse, vol.33, pp.631-642, 2007.

A. Russolillo, A. Moniruzzaman, and L. C. Mccandless, Associations between methadone maintenance treatment and crime: a 17-year longitudinal cohort study of Canadian provincial offenders, Addiction, vol.113, pp.656-667, 2018.

P. G. Barnett, The cost-effectiveness of methadone maintenance as a health care intervention, Addiction, vol.94, pp.479-488, 1999.

A. J. Dunlop, A. L. Brown, and C. Oldmeadow, Effectiveness and cost-effectiveness of unsupervised buprenorphine-naloxone for the treatment of heroin dependence in a randomized waitlist controlled trial, Drug Alcohol Depend, vol.174, pp.181-191, 2017.

E. Kelty and G. Hulse, Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone, Int J Drug Policy, vol.46, pp.54-60, 2017.

M. R. Larochelle, D. Bernson, and T. Land, Medication for opioid use disorder after nonfatal opioid overdose and association with mortality, Ann Intern Med, vol.169, p.137, 2018.

E. T. Moolchan and J. A. Hoffman, Phases of treatment: a practical approach to methadone maintenance treatment, Int J Addict, vol.29, pp.135-160, 1994.

A. H. Smith, K. P. Jensen, and J. Li, Genome-wide association study of therapeutic opioid dosing identifies a novel locus upstream of OPRM1, Mol Psychiatry, vol.22, pp.346-352, 2017.

S. Mouly, V. Bloch, &. Peoc, and K. , Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity, Br J Clin Pharmacol, vol.79, pp.967-977, 2015.

A. Lo, T. Kerr, and K. Hayashi, Factors associated with methadone maintenance therapy discontinuation among people who inject drugs, J Subst Abuse Treat, vol.94, pp.41-46, 2018.

J. Kimber, S. Larney, and M. Hickman, Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study, Lancet Psychiatry, vol.2, pp.901-908, 2015.

M. R. Lofwall and S. L. Walsh, A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world, J Addict Med, vol.8, pp.315-326, 2014.

M. M. Van-handel, C. E. Rose, and E. J. Hallisey, County-Level Vulnerability Assessment for Rapid Dissemination of HIV or HCV Infections Among Persons Who Inject Drugs, United States, J Acquir Immune Defic Syndr, vol.73, pp.323-331, 2016.

D. B. Kandel, M. Hu, and P. Griesler, Increases from 2002 to 2015 in prescription opioid overdose deaths in combination with other substances, Drug Alcohol Depend, vol.178, pp.501-511, 2017.

J. H. Samet, M. Botticelli, and M. Bharel, Methadone in primary care -one small step for congress, one giant leap for addiction treatment, N Engl J Med, vol.379, pp.7-8, 2018.

G. Gauthier, J. K. Eibl, and D. C. Marsh, Improved treatment-retention for patients receiving methadone dosing within the clinic providing physician and other health services (onsite) versus dosing at community (offsite) pharmacies, Drug Alcohol Depend, vol.191, pp.1-5, 2018.

, Portugal): treatment, EMCDDA. Country drug report, vol.2018, 2018.

M. Auriacombe, M. Fatséas, and J. Dubernet, French field experience with buprenorphine, Am J Addict, vol.13, issue.1, pp.17-28, 2004.

, ? Historical article on the French model of OMTs

M. Fatseas and M. Auriacombe, Why buprenorphine is so successful in treating opiate addiction in France, Curr Psychiatry Rep, vol.9, pp.358-364, 2007.

, ? Another important article on the French model of OMTs

M. Kernisant, J. Delorme, and J. Kabore, Trend in buprenorphine and methadone shopping behavior in France from, 2004.

, Presse Med, vol.45, pp.369-375, 2016.

P. Poloméni and R. Schwan, Management of opioid addiction with buprenorphine: french history and current management, Int J Gen Med, vol.7, pp.143-148, 2014.

, Another important and the most recent article on the French model of OMTs

E. Frauger, F. Kheloufi, and Q. Boucherie,

, Therapie, vol.73, pp.511-520, 2018.

T. Barré, F. Vorspan, and M. Fortias, Temporary approval for intranasal naloxone: setting up in a French addiction center

, Therapie, vol.73, pp.495-500, 2018.

, Country drug report 2018 (France): treatment, EMCDDA, 2018.

S. Chavoustie, M. Frost, and O. Snyder, Buprenorphine implants in medical treatment of opioid addiction, Expert Rev Clin Pharmacol, vol.10, issue.8, pp.799-807, 2017.

, ?? An important review encompassing all buprenorphine implants for opioid dependence

A. European-medicines, Buvidal: summary of product characteristics, 2018.

, Buvidal assessment report from the committee for medicinal products for human use (CHMP), ?? The most important pieces of information to know on Buvidal® 51. EMA: European Medicines Agency, 2018.

M. R. Lofwall, S. L. Walsh, and E. V. Nunes, Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial, JAMA Intern Med, vol.178, pp.764-773, 2018.

M. Frost, G. L. Bailey, and N. Lintzeris, Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult outpatients with opioid use disorder, Addiction, vol.114, issue.8, pp.1416-1426, 2019.

S. L. Walsh, S. D. Comer, and M. R. Lofwall, Effect of buprenorphine weekly depot (CAM2038) and hydromorphone blockade in individuals with opioid use disorder: a randomized clinical trial, JAMA Psychiatry, vol.74, pp.894-902, 2017.

J. Neale, C. Tompkins, and R. Mcdonald, Implants and depot injections for treating opioid dependence: qualitative study of people who use or have used heroin, Drug Alcohol Depend, vol.189, pp.1-7, 2018.

J. Neale, C. Tompkins, and J. Strang, Prolonged-release opioid agonist therapy: qualitative study exploring patients' views of 1-week, 1-month, and 6-month buprenorphine formulations, Harm Reduct J, vol.16, p.25, 2019.

C. L. Masson, P. G. Barnett, and K. L. Sees, Cost and cost-effectiveness of standard methadone maintenance treatment compared to enriched 180-day methadone detoxification, Addiction, vol.99, pp.718-726, 2004.

S. Nolan, J. Klimas, and E. Wood, Alcohol use in opioid agonist treatment, Addict Sci Clin Pract, vol.11, p.17, 2016.